cobimetinib

From Aaushi
Jump to navigation Jump to search
[1][2]

Indications

Mechanism of action

Notes

  • investigational; not yet FDA-approved
  • development by Roche/Exelixis[1]

More general terms

References

  1. ↑ 1.0 1.1 1.2 Mescape Oncology. Sept 30, 2014 New Standard in Melanoma: Combo of BRAF and MEK Inhibitors. http://www.medscape.com/viewarticle/832566?nlid=66983_2202
  2. ↑ 2.0 2.1 ClinicalTrials.gov Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma. https://clinicaltrials.gov/study/NCT03224767
Retrieved from "https://aaushi.info/w/index.php?title=A47879&oldid=1163228"